Molecular Diagnostics 2019

Dr. Cobb is the acting Director for Clinical Molecular Diagnostics at Roche Diagnostics Corporation where he serves in a scientific advisory role supporting the laboratory scientific community. He obtained his Ph.D. in Medical Genetics at the University of Alabama at Birmingham ... and trained as a postdoctoral fellowship at Georgetown University Institute for Molecular Genetics. He then completed an American Board of Medical Genetics fellowship program at the National Institutes of Health (NIH) in the National Human Genome Research Institute and is a board certified diplomat of the American College of Medical Genetics. Previously, he was the Head of Scientific Affairs for the global organization where he was responsible for the molecular portfolio's medical plans. He has over 15 years of experience in diagnostics and serves on several international scientific committees and working groups.

Dr. Shawn C. Baker is the Chief Science Officer and co-founder of AllSeq. Having received his Ph.D. at the University of California - Davis, he started his career as a Research Scientist at Illumina when it was a 15-person startup. After spending several years at the bench ... developing gene expression array products, he transitioned to Product Marketing where he led a team in charge of Illuminas Expression and Regulation sequencing portfolio. In 2013 Dr. Baker co-founded AllSeq, establishing the only true sequencing marketplace, matching researchers with service providers based on their needs.

Dr. Hollister is a microbial ecologist and bioinformaticist. She is interested in quantifying and characterizing microbial communities from a wide variety of environments, including the human body. Utilizing high throughput, next-generation DNA and RNA sequence approaches, her ... research seeks to improve our understanding of microbial communities, their distribution across time and space, the ways in which they function, and their influence at broader scales. Dr. Hollister currently serves as the Director of Microbial Ecology and Bioinformatics for the Texas Children's Microbiome Center.

Eugean Jiwanmall's past professional experiences include basic science and clinical research. In his current role as a Senior Research Analyst for Medical Policy & Technology Evaluation at Independence Blue Cross' Claim Payment Policy Department within Facilitated Health ... Networks, he has served as the subject-matter-expert, writer, reviewer, communicator, presenter, consultant, & decision-maker for hundreds of medical policy topics & technology assessments within dozens of clinical disciplines & multiple business areas. Eugean is finishing graduate work in bioethics at the University of Pennsylvania School of Medicine. He holds a bachelor's degree in biological sciences with honors from Drexel University (minor was in business administration), a master's degree of public health in evaluative clinical sciences from Dartmouth Medical School, and an MBA in health care management and economics with honors from Drexel University.

Roger D. Klein, M.D., J.D., serves as Medical Director of Molecular Oncologyo at Bloodcenter Of Wisconsin, Inc. Dr. Klein lead the development of BloodCenter of Wisconsin's Diagnostic Laboratories' newest initiative, which will focus on DNA- and RNA-based testing for evaluation ... of cancer patients.Dr. Klein is a national leader in the advancement of policies related to the implementation of genetic and genomic testing. Specifically, as relates to this webinar, he has been actively engaged in CPT coding, coverage and reimbursement issues with the College of American Pathologists, the Association for Molecular Pathology, and the American Medical Association Molecular Pathology CPT Advisory Group, and governmental panels such as the Medicare Evidence Development and Coverage Advisory Committee. He has played a leading role in the creation and maintenance of the Molecular Pathology section in the CPT Manual.

The discovery of proteinaceous disease biomarkers and their clinical validation is critically important for the enablement of molecular diagnostics and ultimately, precision medicine. In spite of the importance of biomarkers, research done in the last two decades has yielded ... limited success in enhancing the repertoire of protein biomarkers of disease. This apparent dichotomy is in large part due to the fact that the process from discovery to validation is complex and involves a multidisciplinary collaboration across clinical, biochemical and biophysical disciplines and that that many initiatives sought to identify unique markers for a given disease with perfect correlation. Recent advances in better biomarker discovery strategies, clinical sampling and sample storage, better sample preparation methods that consider the inherent instabilities associated with clinical specimens, better discovery methods and analytical instrumentation suited for assay validation and clinical assays together promise to generate better panel tests for disease biomarkers of clinical significance. Hide Biography Dr. Latterich has nearly 20 years of academic and commercial and leadership experience and features an accomplished research career focused on the proteomics-based discovery of novel biomarkers in oncology, respiratory disease and neurodegenerative disorders. Martin is currently CSO at BioScale, a Lexington, MA, based biotechnology corporation commercializing a novel acoustic biomarker quantification platform. Most recently Martin served as a Professor at the Proteogenomics Research Institute for Systems Medicine in San Diego, where his laboratory used proteomics and genomics to discover novel biomarkers of cancer and degenerative disease though a systems biology approach that includes proteomics. He is also the CSO, co-founder and a board member for the non-profit Nicholas Conor Institute for Pediatric Cancer Research. Martin's work at the institute included designing new technologies to enable the better treatment of children with cancer, using personalized medicine technology to match their unique genetic make-up and tumor physiology to available treatment options. He previously served on the faculty of the University of Montreal, McGill University and the Salk Institute. His grant-funded work has been recognized by the 2003 Tier I Canada Research Chair, the 1998 Pew Scholar Award and the 1997 Basil O'Connor Starter Scholar Award. Dr. Latterich also held senior management positions at several biotechnology companies, including Diversa and Illumina, where he headed the proteomics initiatives. He has made significant contributions to the field of cell biology, clinical biomarker discovery, proteomics and genomics. Among his recent discoveries are biomarkers for cancer, respiratory disease and neurodegenerative disorders. Dr Latterich has edited one book on RNAi, is author on over 34 publications in leading scientific journals and is listed on numerous patent applications. Martin is Editor-in-Chief of the scientific journal Proteome Science. He has served on several national and international study sections. He was a postdoctoral fellow in molecular and cell biology in the laboratory of Dr. Randy Schekman at the HHMI and University of California, Berkeley. Dr. Latterich earned his Ph.D. in cell biology and a B.Sc. in biochemistry and molecular biology from Durham University, U.K.

Dr. Christopher Mason completed his dual B.S. in Genetics and Biochemistry (2001) from University of Wisconsin-Madison, his Ph.D. in Genetics (2006) from Yale University, and then completed post-doctoral training in clinical genetics (2009) at Yale Medical School, and a joint ... post-doctoral Fellow of Genomics, Ethics, and Law at Yale Law School (2009). He is currently an Associate Professor at Weill Cornell Medicine, with appointments at the Tri-Institutional Program on Computational Biology and Medicine, the Meyer Cancer Center, and the Feil Family Brain and Mind Research Institute. The Mason laboratory develops and deploys new biochemical and computational methods in functional genomics to elucidate the genetic basis of human disease and human physiology. We create and explore novel techniques in next-generation sequencing and algorithms for: tumor evolution, genome evolution, DNA and RNA modifications, and genome/epigenome engineering. We also work closely with NIST/FDA to build international standards for these methods, to ensure clinical-quality genome measurements/editing. We also work with NASA to build integrated molecular portraits of genomes, epigenomes, transcriptomes, and metagenomes for astronauts, which establish the molecular foundations and genetic defenses for enabling long-term human space travel. He has won the NIH's Transformative R01 Award, the NASA Group Achievement Award, the Pershing Square Sohn Cancer Research Alliance Young Investigator award, the Hirschl-Weill-Caulier Career Scientist Award, the Vallee Scholar Award, the CDC Honor Award for Standardization of Clinical Testing, and the WorldQuant Foundation Scholar Award. He has >130 peer-reviewed papers that have been featured on the covers of Nature, Science, Cell Host and Microbe, Nature Biotechnology, Nature Microbiology, and many others.He was named as one of the "Brilliant Ten" Scientists by Popular Science, featured as a TEDMED speaker, and called "The Genius of Genetics" by 92Y.

Khyati Shah received her Ph.D. in Molecular Pharmacology from the University of the Pacific, Stockton, California. Her graduate research was completed in the lab of Jesika Faridi, Ph.D. Her work focused on the investigation of the mechanism of Akt induced tamoxifen resistance in ... breast cancer. Currently, Khyati is the research fellow in Bandyopadhyay Lab since 2015. Her project involves investigation of the mechanism of resistance to targeted and immuno-therapy using systems biology approach. She has three-first author publications in the reputed peer-reviewed journals and 7 oral and 15 poster talks on the use of systemic genomics and proteomic approach to design rational combination therapy and to increase the durability of therapeutic response.